Energy, Cognition & Mood
Best Peptides for Sleep & Insomnia: Clinical Evidence (2026)
An evidence-ranked look at the peptides marketed for sleep — DSIP, MK-677, epitalon, CJC-1295 and ipamorelin. The honest headline: no peptide is a proven insomnia treatment, and the best human data are tiny and decades old.
Sleep & insomniaHuman evidenceGH secretagoguesCircadian/melatoninEvidence-graded
The quick verdict
No peptide is a proven insomnia treatment — here is what the human evidence actually shows for DSIP, MK-677, epitalon, CJC-1295 and ipamorelin, ranked honestly by data quality.
- Best overall
- DSIP (delta sleep-inducing peptide) — The only peptide studied directly in human insomniacs with sleep as the primary endpoint — two 1981 double-blind crossover trials — though the data are tiny, dated and unreplicated (Grade B, low confidence).
- Best value
- MK-677 (ibutamoren) — Not a peptide, but the honest class benchmark: the single best objective polysomnography RCT of any GH-secretagogue, showing more deep sleep and REM — offset by a real insulin-resistance cost.
- Best for Older adults with low nocturnal melatonin
- Epitalon — Reported to restore nocturnal melatonin and normalize the circadian rhythm in the elderly — a plausible root-cause angle, but measured on melatonin surrogates, not on sleep itself.
How we evaluated
We ranked each compound strictly by the quality and directness of its HUMAN sleep evidence, separating human data from preclinical mechanism and from anecdote. Regulatory and anti-doping status is date-stamped to 2026. This is editorial analysis of published research, not medical advice or a sourcing guide.
- Directness of human sleep data. Whether the compound was studied with sleep or insomnia as an actual endpoint in humans, versus a surrogate (melatonin) or pure mechanism.
- Study design quality. Double-blind, placebo-controlled and crossover designs rank above open-label or single-laboratory work; polysomnography (objective) ranks above self-report.
- Replication & sample size. Findings replicated across groups and in larger samples outrank single tiny trials; we flag decades-old, unreplicated data explicitly.
- Safety & regulatory status. We weigh documented metabolic/oncologic caveats, FDA/503A status, and WADA prohibition against any purported benefit.
Rating scale: 1–5 stars, reflecting strength and directness of human sleep evidence (not popularity or marketing). 5 = replicated modern human trials; 1 = mechanistic/anecdotal only.
Last verified .
At a glance
| # | Name | Evidence | Rating | Best for | Pricing |
|---|---|---|---|---|---|
| 1 | DSIP (Delta Sleep-Inducing Peptide) | B | 3.0 | Understanding the ceiling of direct peptide sleep evidence — which is thin, dated and unreplicated | Not FDA-approved; sold as research chemical |
| 2 | MK-677 (Ibutamoren) | B | 3.0 | Benchmarking the GH-secretagogue class's real (but caveated) objective sleep signal | Not FDA-approved; sold as research chemical |
| 3 | Epitalon (Epithalon, AEDG) | C | 2.5 | Older adults with documented low nocturnal melatonin considering a circadian, not sedative, angle | Not FDA-approved; under 503A/PCAC review |
| 4 | CJC-1295 (without DAC / Mod GRF 1-29) | D | 1.5 | Illustrating how a plausible mechanism gets marketed far ahead of any human sleep evidence | Not FDA-approved; sold as research chemical |
| 5 | Ipamorelin | D | 1.5 | Understanding why 'raises GH' does not equal 'improves sleep' for a selective secretagogue | Not FDA-approved; sold as research chemical |
DSIP (Delta Sleep-Inducing Peptide)
The only peptide studied directly in human insomniacs — but tiny and 45 years old
DSIP ranks first because it is the only compound in this field studied directly in human insomniacs under double-blind conditions with sleep as the primary endpoint. Two small ~1981 crossover trials from the Schoenenberger/Schneider-Helmert group tell the whole human story: in healthy volunteers (n=6), slow IV DSIP increased daytime sleep by roughly 59% over the post-dose window and improved sleep efficiency without the EEG signature of classic sedation; in chronic insomniacs (n=6), acute IV DSIP produced longer sleep, fewer interruptions and no daytime sedation, described as a normalizing influence on sleep regulation. The authors framed it as sustaining natural sleep rather than forcing it. The problem is that this is the weakest 'best evidence' of any peptide condition: total human sleep N is about a dozen people, the trials are ~45 years old and never replicated in a modern RCT, the broader literature is mixed, and after 50 years no DSIP receptor, gene or precursor has been identified. Recent supportive work is preclinical only (a DSIP-fusion peptide in a PCPA-induced insomnia mouse model). The grade is B strictly because the trials were double-blind and crossover; the confidence is low.
Strengths
- Only peptide studied directly in human insomniacs with sleep as the primary endpoint
- Double-blind crossover designs; reported a normalizing, non-sedating effect on disturbed sleep
- Generally well tolerated in the short human trials (no daytime sedation)
Weaknesses
- Total human sleep N is ~12 people across two 1981 trials, never replicated in a modern RCT
- No identified receptor, gene or precursor after ~50 years; broader literature is mixed
- Paradoxical anesthesia signal (raised heart rate, reduced anesthetic depth); subcutaneous grey-market route is not the validated IV route
- Best for
- Understanding the ceiling of direct peptide sleep evidence — which is thin, dated and unreplicated
- Pricing
- Not FDA-approved; sold as research chemical
Source: Schneider-Helmert & Schoenenberger, Experientia 1981 (PMID 7028502)
MK-677 (Ibutamoren)
Best objective (polysomnography) sleep data — but a non-peptide with a metabolic cost
MK-677 is an orally active, non-peptide ghrelin-receptor (GHS-R1a) mimetic — chemically not a peptide, but pharmacologically the same axis as ipamorelin, which makes it the honest benchmark for whether GH-secretagogues improve sleep. It earns second place because it has the single best-designed objective human sleep study in this entire category. In a double-blind, placebo-controlled crossover polysomnography trial, 25 mg oral MK-677 produced roughly 50% more stage-IV (deep) sleep and over 20% more REM in young adults (n=8), and cut abnormal sleep episodes from 42% to 8%; in older adults (n=6) it increased REM by about 50%, shortened REM latency and reduced sleep deviations. That is consistent with the broader finding that ghrelin promotes slow-wave sleep in men. The caveats are serious: the samples are tiny (n=8 and n=6), the subjects were healthy volunteers rather than diagnosed insomniacs, the clinical significance of these architecture changes was never confirmed in longer or larger trials, and chronic MK-677 raises GH/IGF-1 and carries a documented insulin-resistance and raised-fasting-glucose signal — a meaningful metabolic trade-off. It is not FDA-approved and is WADA-prohibited at all times as a GH secretagogue.
Strengths
- Best objective polysomnography evidence of any GH-secretagogue (placebo-controlled crossover)
- Increased deep (stage-IV) sleep and REM in both young and older adults
- Orally active, so no injection; well tolerated for sleep architecture in the short trial
Weaknesses
- Not a peptide; tiny samples in healthy volunteers, not diagnosed insomniacs
- Chronic use raises fasting glucose and reduces insulin sensitivity — a real metabolic cost
- Not FDA-approved; WADA-prohibited at all times; architecture gains never confirmed in larger trials
- Best for
- Benchmarking the GH-secretagogue class's real (but caveated) objective sleep signal
- Pricing
- Not FDA-approved; sold as research chemical
Source: Copinschi et al., Neuroendocrinology 1997 (PMID 9349662)
Epitalon (Epithalon, AEDG)
Circadian/melatonin restoration in older adults — a surrogate, not measured sleep
Epitalon (AEDG, a synthetic tetrapeptide) ranks here because its sleep relevance is indirect — via melatonin and circadian normalization in older adults — and there is no controlled insomnia or polysomnography trial of it. Small, mostly single-laboratory (Khavinson group) and mostly unblinded human work reports that epitalon and its parent extract epithalamin restore nocturnal melatonin secretion in aged subjects with low baseline pineal function and normalize the circadian melatonin rhythm; a small (~n=75) placebo-controlled sublingual study reported a ~1.6-fold rise in urinary 6-sulfatoxymelatonin plus clock-gene shifts. The biological premise is reasonable and appealingly root-cause: rebuild the circadian melatonin signal rather than force sleep pharmacologically, which could plausibly consolidate sleep in the melatonin-deficient elderly. But the crucial limitation is that all of these are melatonin or circadian surrogates, not sleep outcomes — no study measured insomnia severity or polysomnographic sleep after epitalon. Rat data are contradictory (epitalon failed to raise melatonin in rats), and the human work is small, unblinded and single-group. That is why we grade the melatonin/circadian claim B but the insomnia claim itself only C. There is also a theoretical oncologic caveat via telomerase/ALT modulation, arguing for caution in anyone with active or prior malignancy.
Strengths
- Reported to restore nocturnal melatonin and normalize the circadian rhythm in older adults
- Root-cause logic (rebuild the melatonin signal) rather than sedation
- One placebo-controlled sublingual study showed a measurable melatonin-metabolite rise
Weaknesses
- No controlled insomnia or polysomnography trial — endpoints are melatonin/circadian surrogates only
- Human work is small, largely unblinded and single-laboratory; rat melatonin data are contradictory
- Theoretical telomerase/oncologic caveat; no large safety dataset
- Best for
- Older adults with documented low nocturnal melatonin considering a circadian, not sedative, angle
- Pricing
- Not FDA-approved; under 503A/PCAC review
Source: Effect of epithalamin on pineal melatonin circadian rhythm in the elderly, 2004 (PMID 15452611)
CJC-1295 (without DAC / Mod GRF 1-29)
Well-characterized GHRH agonist on paper — zero human sleep data
CJC-1295 without DAC (Mod GRF 1-29) is a well-characterized GHRH-receptor agonist on paper, and GHRH does promote slow-wave sleep in men — but there is no human sleep trial of this molecule, and no human RCT of the no-DAC peptide for any outcome. Its GH-release pharmacology is animal and in-vitro only; for example, a rat study showed roughly 4x the GH area-under-curve over two hours versus native GRF. The human-trial data in this family belong to the DAC version, which raised GH/IGF-1 for days — and even those studies measured hormones, not sleep. The entire 'better deep sleep' claim is therefore a mechanistic extrapolation from the genuine GHRH-to-slow-wave-sleep coupling, and it is undercut by the sex-difference data showing GHRH impaired sleep in healthy young women. Community use cites roughly 100 µg subcutaneously, often dosed pre-sleep to align a GH pulse with nocturnal slow-wave sleep and frequently co-injected with ipamorelin, but no validated human dose exists. Reported effects include injection-site reactions, flushing, transient headache, water retention and somnolence consistent with a GH pulse, plus theoretical insulin-resistance and IGF-1 proliferation concerns and uncontrolled product purity. It is not FDA-approved, was not recommended for the 503A bulks list, and is WADA-prohibited at all times.
Strengths
- Genuine GHRH-receptor agonist; the underlying GHRH-to-slow-wave-sleep coupling is real biology
- Rat data show strong GH release; short half-life allows pulse-timed dosing in theory
- Class DAC version has human pharmacodynamic (GH/IGF-1) data, confirming target engagement
Weaknesses
- No human sleep trial and no human RCT of the no-DAC peptide for any outcome
- Sleep benefit is mechanistic extrapolation, undercut by GHRH impairing sleep in women
- Not FDA-approved, not recommended for 503A bulks list, WADA-prohibited; uncontrolled purity
- Best for
- Illustrating how a plausible mechanism gets marketed far ahead of any human sleep evidence
- Pricing
- Not FDA-approved; sold as research chemical
Ipamorelin
Cleanly releases GH in humans — but no sleep trial, and its one efficacy RCT was negative
Ipamorelin's standout fact is that it cleanly releases growth hormone in humans (Grade B pharmacodynamics), but that is not a sleep outcome, and no ipamorelin-specific human sleep trial exists. Ipamorelin reliably raises GH in humans in Phase-1 work, and its one efficacy RCT — for postoperative ileus, a different indication, in about 114 patients — was negative on its primary endpoint though well tolerated. The sleep benefit is purely Grade D, extrapolated from the fact that GH peaks during slow-wave sleep and from native ghrelin's slow-wave-sleep effect in men. That extrapolation is shakier than it looks: the ghrelin slow-wave-sleep study used native ghrelin, not ipamorelin, and ipamorelin is deliberately engineered to be selective for GH release, so it does not necessarily replicate ghrelin's central sleep actions. The popular CJC-1295 plus ipamorelin 'sleep stack' pairs a GHRH-receptor agonist with this ghrelin-receptor agonist, and the synergy is real pathway pharmacology — but there are no human RCTs of the combination for sleep or any clinical outcome. Community use cites subcutaneous doses of roughly 100–300 µg pre-sleep, often with CJC-1295, none validated by any controlled trial. Class safety concerns include transient hyperglycemia and insulin resistance, water retention and theoretical IGF-1 proliferation risk. It is not FDA-approved and is WADA-prohibited at all times.
Strengths
- Reliably and cleanly raises GH in humans (well-characterized Phase-1 pharmacodynamics)
- Well tolerated in its human studies; part of a mechanistically coherent GHRH+ghrelin stack
- Selective GH release avoids some off-target ghrelin effects (e.g., cortisol/prolactin)
Weaknesses
- No human sleep trial; its only efficacy RCT (postoperative ileus) was negative
- Sleep claim extrapolated from native-ghrelin data, which ipamorelin's selectivity may not replicate
- No human RCT of the CJC-1295 stack for sleep; not FDA-approved; WADA-prohibited
- Best for
- Understanding why 'raises GH' does not equal 'improves sleep' for a selective secretagogue
- Pricing
- Not FDA-approved; sold as research chemical
Source: Beck et al., Int J Colorectal Dis 2014 (PMID 25331030)
Frequently asked
What is the single best peptide for sleep based on human evidence?
There is no clear winner, and none is proven. DSIP has the most direct human sleep evidence — two small 1981 double-blind crossover trials in insomniacs and healthy volunteers, graded B. MK-677, a non-peptide GH-secretagogue, has the best objective polysomnography data: one small placebo-controlled crossover RCT, also graded B. Both rest on tiny samples of roughly a dozen people, so neither reaches the bar of a modern, adequately powered trial. If your only benchmark is quality of human data, DSIP and MK-677 effectively tie for first — and both carry heavy caveats, from DSIP's missing receptor to MK-677's insulin-resistance signal.
Do CJC-1295 and ipamorelin actually improve deep sleep?
Not proven — this is Grade D for sleep. The growth-hormone to slow-wave-sleep coupling is real class pharmacology: GH is preferentially released during deep sleep, and GHRH appears to actively promote slow-wave sleep. But there is no human sleep trial of either peptide, nor of the popular CJC-1295 plus ipamorelin stack, and ipamorelin's only efficacy RCT (for a different indication) was negative. The pre-sleep dosing logic — timing a GH pulse to the nocturnal slow-wave-sleep window — is a mechanistic extrapolation, not a demonstrated clinical outcome. Treat any 'better deep sleep' claim for these peptides as anecdotal until human sleep trials exist.
Is DSIP a sedative?
No. In the controlled 1981 trials, DSIP produced a normalizing, non-sedating effect on disturbed sleep — the authors described it as sustaining natural sleep functions rather than forcing sleep, and it did not show the classic EEG signature of a sedative. Paradoxically, when used as an anesthesia adjunct it increased heart rate and reduced anesthetic depth, the opposite of a sedative. This matters because much marketing frames DSIP as a calming, stress-lowering sleep aid; in a controlled human test DSIP did not even suppress cortisol. It is better understood as a putative sleep-regulating peptide with thin, dated evidence than as a hypnotic.
Can epitalon help age-related insomnia?
Possibly, but this is inferred rather than demonstrated. Epitalon and its parent extract epithalamin are reported to restore nocturnal melatonin secretion and normalize the circadian rhythm in older adults with low pineal output. The premise is reasonable: more nocturnal melatonin can mean better-consolidated sleep in the melatonin-deficient elderly. But every one of those endpoints is a melatonin or circadian surrogate, not measured sleep — no controlled insomnia or polysomnography trial of epitalon exists, and the human work is small, largely unblinded and single-laboratory. Marketing epitalon as an insomnia treatment runs well ahead of the evidence, which is why the insomnia claim specifically is graded low.
Why might GH-secretagogues affect men and women differently?
Because the GHRH effect on sleep is sexually dimorphic. Pulsatile GHRH increased slow-wave sleep and lowered cortisol in healthy young men, and native ghrelin similarly promoted slow-wave sleep in men. But in healthy young women, systemic GHRH actually impaired sleep — it reduced stage-4 deep sleep and early-night REM. This is a major reason to treat the blanket claim that GH-axis peptides improve deep sleep as unsettled and population-dependent. Most supportive mechanistic human data were generated in men, so extrapolating a deep-sleep benefit to women is not just unproven but potentially backwards. Mechanism and outcome are not the same thing.
Are any of these peptides FDA-approved or legal for sleep in 2026?
None is FDA-approved for insomnia or any indication, and most are sold as research chemicals not for human use. As of 2026, DSIP (emideltide) and epitalon were removed from the FDA's 503A interim Category 2 list in April 2026 and scheduled for Pharmacy Compounding Advisory Committee review on July 23-24, 2026 — removal from Category 2 is not approval and does not authorize compounding. CJC-1295 and ipamorelin were not recommended for the 503A bulks list and remain the least certain of the group. All the GH-secretagogues are prohibited at all times in sport under WADA S2. None is a controlled substance, but lack of scheduling does not make human use legal.